These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

394 related articles for article (PubMed ID: 27978552)

  • 41. Concurrent carboplatin, etoposide and thoracic radiation for poor-risk stage III non-small-cell lung carcinoma: a pilot study.
    Lau DH; Ryu JK; Gandara DR; Rosenthal SA
    Int J Radiat Oncol Biol Phys; 1997 Apr; 38(1):157-61. PubMed ID: 9212018
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Induction chemotherapy with carboplatin/paclitaxel followed by surgery or standard radiotherapy and concurrent daily low-dose cisplatin for locally advanced non-small cell lung cancer (NSCLC).
    De Candis D; Stani SC; Bidoli P; Bedini VA; Potepan P; Navarria P; Aglione S; Bajetta E
    Am J Clin Oncol; 2003 Jun; 26(3):265-9. PubMed ID: 12796598
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A phase II study of paclitaxel, carboplatin, and hyperfractionated radiation therapy for locally advanced inoperable non-small-cell lung cancer (a Vanderbilt Cancer Center Affiliate Network Study).
    Choy H; Devore RF; Hande KR; Porter LL; Rosenblatt P; Yunus F; Schlabach L; Smith C; Shyr Y; Johnson DH
    Int J Radiat Oncol Biol Phys; 2000 Jul; 47(4):931-7. PubMed ID: 10863062
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Durvalumab in combination with chemoradiotherapy for patients with unresectable stage III non-small-cell lung cancer: Results from the phase 1 CLOVER study.
    Kim DW; Chul Cho B; Pachipala K; Kim SW; Wang CL; Chang GC; Ahn MJ; Alvarez R; Chiu CH; Trigo J; Estival A; Karam SD; O'Brien C; Gowda H; Jiang H; Bauman JE
    Lung Cancer; 2024 Apr; 190():107530. PubMed ID: 38471416
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Phase III randomised trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non-small-cell lung cancer: a cooperative multinational trial.
    Rosell R; Gatzemeier U; Betticher DC; Keppler U; Macha HN; Pirker R; Berthet P; Breau JL; Lianes P; Nicholson M; Ardizzoni A; Chemaissani A; Bogaerts J; Gallant G
    Ann Oncol; 2002 Oct; 13(10):1539-49. PubMed ID: 12377641
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Phase II trial of induction high-dose chemotherapy followed by surgical resection and radiation therapy for patients with marginally resectable non-small cell carcinoma of the lung.
    Schilder RJ; Goldberg M; Millenson MM; Movsas B; Rogatko A; Rogers B; Langer CJ
    Lung Cancer; 2000 Jan; 27(1):37-45. PubMed ID: 10672782
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Assessment of chemotherapy regimens on radiation pneumonitis in patients with unresectable stage III non-small-cell lung cancer after definitive chemoradiotherapy.
    Sakaguchi T; Ito K; Furuya N; Morikawa K; Fujiwara K; Nishii Y; Inoue T; Hataji O; Mineshita M
    Thorac Cancer; 2021 Jul; 12(13):2024-2030. PubMed ID: 34002492
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Carboplatin/etoposide/radiation plus escalating doses of paclitaxel in stage III non-small cell lung cancer: a preliminary report.
    Bonomi P; Faber LP; Recine D; Lincoln S
    Semin Oncol; 1995 Aug; 22(4 Suppl 9):42-7. PubMed ID: 7644927
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Paclitaxel, carboplatin, and extended-schedule etoposide in the treatment of small-cell lung cancer: comparison of sequential phase II trials using different dose-intensities.
    Hainsworth JD; Gray JR; Stroup SL; Kalman LA; Patten JE; Hopkins LG; Thomas M; Greco FA
    J Clin Oncol; 1997 Dec; 15(12):3464-70. PubMed ID: 9396399
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Concurrent radiochemotherapy with vinorelbine plus cisplatin or carboplatin in patients with locally advanced non-small-cell lung cancer (NSCLC) and an increased risk of treatment complications. Preliminary results.
    Semrau S; Bier A; Thierbach U; Virchow C; Ketterer P; Fietkau R
    Strahlenther Onkol; 2003 Dec; 179(12):823-31. PubMed ID: 14652671
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Phase II study of vinorelbine plus carboplatin with concurrent radiotherapy in elderly patients with non-small cell lung cancer.
    Yamaguchi M; Hirata H; Ebi N; Araki J; Seto T; Maruyama R; Akamine S; Inoue Y; Semba H; Sasaki J; Okamoto T
    Jpn J Clin Oncol; 2020 Mar; 50(3):318-324. PubMed ID: 31804689
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Five-year results of a phase II trial of hyperfractionated radiotherapy and concurrent daily cisplatin chemotherapy for stage III non-small-cell lung cancer.
    Keene KS; Harman EM; Knauf DG; McCarley D; Zlotecki RA
    Am J Clin Oncol; 2005 Jun; 28(3):217-22. PubMed ID: 15923791
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Therapeutic effects and prognostic factors for the limited-stage small cell lung cancer treated with multidisciplinary therapy].
    Dong XJ; Wang MZ; Zhong W; Zhang L; Zhang XT; Zhao J; Xia Y; Li LY
    Zhonghua Zhong Liu Za Zhi; 2012 Mar; 34(3):216-21. PubMed ID: 22780978
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Radiotherapy and chemotherapy in locally advanced non-small cell lung cancer: preclinical and early clinical data.
    Reboul FL
    Hematol Oncol Clin North Am; 2004 Feb; 18(1):41-53. PubMed ID: 15005280
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Phase I trial of concurrent thoracic radiation and continuous infusion cisplatin and etoposide in stage III non-small cell lung cancer.
    Kalemkerian GP; Belzer K; Wozniak AJ; Gaspar LE; Valdivieso M; Kraut MJ
    Lung Cancer; 1999 Sep; 25(3):175-82. PubMed ID: 10512128
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Phase II study of intensive chemotherapy with carboplatin, ifosfamide and etoposide plus recombinant human granulocyte colony-stimulating factor and sequential radiotherapy in locally advanced, unresectable non-small-cell lung cancer.
    Scagliotti GV; Ricardi U; Crinó L; Maranzano E; De Marinis F; Morandi MG; Meacci L; Marangolo M; Emiliani E; Rosti G; Figoli F; Bolzicco G; Masiero P; Gentile A; Tonato M
    Cancer Chemother Pharmacol; 1996; 38(6):561-5. PubMed ID: 8823499
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Phase II trial of cisplatin/etoposide and concurrent radiotherapy followed by paclitaxel/carboplatin consolidation for limited small-cell lung cancer: Southwest Oncology Group 9713.
    Edelman MJ; Chansky K; Gaspar LE; Leigh B; Weiss GR; Taylor SA; Crowley J; Livingston R; Gandara DR
    J Clin Oncol; 2004 Jan; 22(1):127-32. PubMed ID: 14701775
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Single-center comparison of multiple chemotherapy regimens for concurrent chemoradiotherapy in unresectable stage III non-small-cell lung cancer.
    Tabchi S; Blais N; Campeau MP; Tehfe M
    Cancer Chemother Pharmacol; 2017 Feb; 79(2):381-387. PubMed ID: 28083648
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Outcomes treating stage III non-small cell lung carcinoma with curative-intent radiotherapy and concurrent carboplatin-paclitaxel chemotherapy.
    Trinh H; Pinkham MB; Lehman M; Zarate D; Dauth M; McGrath M; McCaffrey E; Mai GT; Horwood K
    Clin Respir J; 2016 Jul; 10(4):428-34. PubMed ID: 25353367
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Induction chemotherapy with carboplatin, irinotecan, and paclitaxel followed by high dose three-dimension conformal thoracic radiotherapy (74 Gy) with concurrent carboplatin, paclitaxel, and gefitinib in unresectable stage IIIA and stage IIIB non-small cell lung cancer.
    Stinchcombe TE; Morris DE; Lee CB; Moore DT; Hayes DN; Halle JS; Rivera MP; Rosenman JG; Socinski MA
    J Thorac Oncol; 2008 Mar; 3(3):250-7. PubMed ID: 18317067
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.